Autotelic Bio, an ASO (Anti-sense Oligonucleotide)-based innovative new drug development company, announced on December 11 that it has raised strategic investment worth of KRW 3 billion in 10 months since its Series A funding in February this year. The strategic investment is in the form of a bridge to Series B investment expected in the third quarter of 2021, and large domestic pharmaceutical companies such as ST Pharm and Jeil Pharmaceutical will participate in the investment for joint development partnerships, an Autotelic Bio investment official explained. 

Autotelic Bio is developing Immuno-Target Dual Action Onco-therapeutic based on oligonucleotide. By this strategic investment funding, Autotelic Bio is planning to develop platform technology and new anticancer drugs. In particular, ST Pharm, which participated in this strategic investment, is the third-largest production facility in the world and the only company in Korea with cGMP facilities, has produced clinical samples to be used in the clinical trials of ATB-301 (combination therapy of trabedersen and interleukin-2). 

So far, Autotelic Bio has raised about KRW 13 billion, including KRW 8 billion in Series A investment. Tai Kim, CEO of Autotelic Bio, said, "Through this strategic partnership to develop global innovative new drugs related to the strategic investment, we will focus on establishing a foundation for Autotelic Bio to grow into an oligonucleotide-based global innovative new drug development company."